136 related articles for article (PubMed ID: 23620531)
1. Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs.
Kesselheim AS; Franklin JM; Avorn J; Duke JD
BMJ Qual Saf; 2013 Sep; 22(9):727-34. PubMed ID: 23620531
[TBL] [Abstract][Full Text] [Related]
2. Adverse drug reaction labelling for atomoxetine, methylphenidate and modafinil: comparison of product information for oral formulations in Australia, Denmark and the United States.
Aagaard L; Hansen EH
Curr Drug Saf; 2013 Jul; 8(3):162-8. PubMed ID: 23914751
[TBL] [Abstract][Full Text] [Related]
3. Bringing greater transparency to "black box" warnings.
Buckley NA; Rossi S
Clin Toxicol (Phila); 2011 Jul; 49(6):448-51. PubMed ID: 21824055
[TBL] [Abstract][Full Text] [Related]
4. Consistency in the safety labeling of bioequivalent medications.
Duke J; Friedlin J; Li X
Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584
[TBL] [Abstract][Full Text] [Related]
5. Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents.
Cornelius VR; Liu K; Peacock J; Sauzet O
BMJ Open; 2016 Mar; 6(3):e010599. PubMed ID: 26996819
[TBL] [Abstract][Full Text] [Related]
6. Different indications, warnings and precautions, and contraindications for the same drug--an international comparison of prescribing information for commonly used psychiatric drugs.
Pfistermeister B; Schenk C; Kornhuber J; Bürkle T; Fromm MF; Maas R
Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):329-33. PubMed ID: 23280570
[TBL] [Abstract][Full Text] [Related]
7. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
[TBL] [Abstract][Full Text] [Related]
8. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs.
Wang LM; Wong M; Lightwood JM; Cheng CM
Ann Pharmacother; 2010 Jan; 44(1):28-34. PubMed ID: 20040698
[TBL] [Abstract][Full Text] [Related]
9. Medication safety: opening up the black box.
Mintzes B
BMJ Qual Saf; 2013 Sep; 22(9):702-4. PubMed ID: 23832923
[No Abstract] [Full Text] [Related]
10. FDA boxed warnings: how to prescribe drugs safely.
O'Connor NR
Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888
[TBL] [Abstract][Full Text] [Related]
11. Discrepancies in listed adverse drug reactions in pharmaceutical product information supplied by the regulatory authorities in Denmark and the USA.
Eriksson R; Aagaard L; Jensen LJ; Borisova L; Hørlück D; Brunak S; Hansen EH
Pharmacol Res Perspect; 2014 Jun; 2(3):e00038. PubMed ID: 25505588
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of drug safety information using large-scale adverse drug reactions database].
Morikawa K
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2011; (129):1-26. PubMed ID: 22259840
[TBL] [Abstract][Full Text] [Related]
13. Food and Drug Administration monitoring of adverse drug reactions.
Sills JM; Tanner LA; Milstien JB
Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
[TBL] [Abstract][Full Text] [Related]
14. An analysis of legal warnings after drug approval in Thailand.
Sriphiromya P; Theeraroungchaisri A
Regul Toxicol Pharmacol; 2015 Feb; 71(1):108-13. PubMed ID: 25445000
[TBL] [Abstract][Full Text] [Related]
15. Discrepancies in the Evidence and Recommendation Levels of Pregnancy Information in Prescription Drug Labeling in the United States, United Kingdom, Japan, and Korea.
Noh Y; Yoon D; Song I; Jeong HE; Bae JH; Shin JY
J Womens Health (Larchmt); 2018 Sep; 27(9):1086-1092. PubMed ID: 29878862
[TBL] [Abstract][Full Text] [Related]
16. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
Yeh JS; Sarpatwari A; Kesselheim AS
Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
[TBL] [Abstract][Full Text] [Related]
17. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
Ladewski LA; Belknap SM; Nebeker JR; Sartor O; Lyons EA; Kuzel TC; Tallman MS; Raisch DW; Auerbach AR; Schumock GT; Kwaan HC; Bennett CL
J Clin Oncol; 2003 Oct; 21(20):3859-66. PubMed ID: 14551305
[TBL] [Abstract][Full Text] [Related]
18. Semantic processing to identify adverse drug event information from black box warnings.
Culbertson A; Fiszman M; Shin D; Rindflesch TC
AMIA Annu Symp Proc; 2014; 2014():442-8. PubMed ID: 25954348
[TBL] [Abstract][Full Text] [Related]
19. Paediatric adverse drug reaction reporting: understanding and future directions.
Carleton BC; Smith MA; Gelin MN; Heathcote SC
Can J Clin Pharmacol; 2007; 14(1):e45-57. PubMed ID: 17297195
[TBL] [Abstract][Full Text] [Related]
20. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling.
Willy ME; Li Z
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):201-6. PubMed ID: 15255086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
